Question special
Lead Moderator

Thanks everyone for commenting and sharing your knowledge with us so far. Some comments have already been made about differences in VPTD and infant mortality between the two ART arms in the study. Specifically, better HIV-free survival was found in infants in the zidovudine-Art versus the tenofovir-ART in period 2. In the discussion, there is brief mention a possible confounder accounting for this result. Could the authors and experts further elaborate on the potential biologic etiology proposed and what specific steps future research should take to better illuminate the pharmacokinetic interaction between drugs taken concomitantly?